Investment Thesis
Autonomix Medical is a pre-revenue medical device company with zero revenue and significant ongoing cash burn of $9.4M annually, indicating the company has not yet achieved commercial traction. With only $9.9M in cash and negative operating cash flow, the company has approximately 12 months of runway before potential capital depletion, absent additional funding or a major inflection in commercialization.
AMIX Strengths
- Strong current ratio of 6.18x indicates short-term liquidity to meet near-term obligations
- Conservative balance sheet with low debt-to-equity ratio of 0.17x minimizes financial leverage risk
- Minimal capital expenditure of $7K suggests asset-light business model focused on development rather than infrastructure
AMIX Risks
- Zero revenue despite being a publicly traded company indicates inability to commercialize product or gain market adoption
- Negative operating cash flow of -$9.4M combined with $9.9M cash balance creates imminent funding requirement within 12 months
- Massive negative returns on equity (-164.1%) and assets (-137.6%) demonstrate value destruction and failed product-market fit
- No insider activity in past 90 days suggests lack of management confidence and potential disengagement
- Complete absence of gross profit prevents assessment of unit economics and operational viability
Key Metrics to Watch
- Revenue recognition and commercial traction milestones
- Cash burn rate and remaining runway before funding requirement
- Operating cash flow improvement trajectory and path to breakeven
AMIX Financial Metrics
AMIX Profitability Ratios
AMIX Balance Sheet & Liquidity
AMIX 5-Year Financial Trend
5-Year Trend Summary: Autonomix Medical, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-14.82 indicates the company is currently unprofitable.
AMIX Growth Metrics (YoY)
AMIX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | N/A | -$2.7M | $-0.36 |
| Q2 2026 | N/A | -$2.7M | $-1.38 |
| Q1 2026 | N/A | -$2.7M | $-1.07 |
| Q3 2025 | N/A | -$865.0K | $-1.46 |
| Q2 2024 | N/A | -$865.0K | $-2.47 |
| Q1 2024 | N/A | -$865.0K | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AMIX Capital Allocation
AMIX SEC Filings
Access official SEC EDGAR filings for Autonomix Medical, Inc. (CIK: 0001617867)